Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2
N. R. Jena
Chemical Physics Impact (2021) Vol. 2, pp. 100011-100011
Open Access | Times Cited: 25

Showing 25 citing articles:

Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
An evaluation of spirooxindoles as blocking agents of SARS-CoV-2 spike/ACE2 interaction: synthesis, biological evaluation and computational analysis
Albert Enama Ehinak, Maloba M. M. Lobe, Donatus Bekindaka Eni, et al.
Medicinal Chemistry Research (2025)
Open Access
Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main protease
Merve Yuce, Erdem Cicek, Tuğçe İnan, et al.
Proteins Structure Function and Bioinformatics (2021) Vol. 89, Iss. 11, pp. 1425-1441
Open Access | Times Cited: 39
SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review
Jahangir Emrani, Maryam Ahmed, Liesl K. Jeffers-Francis, et al.
International Journal of Biological Macromolecules (2021) Vol. 193, pp. 1249-1273
Open Access | Times Cited: 34
Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity
Rania Hamdy, Bahgat Fayed, Ahmed Mostafa, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9057-9057
Open Access | Times Cited: 21
Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2
N. R. Jena, Suyash Pant, Hemant Kumar Srivastava
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 14, pp. 6381-6397
Open Access | Times Cited: 17
SAR based Review on Diverse Heterocyclic Compounds with Various Potential Molecular Targets in the Fight against COVID-19: A Medicinal Chemist Perspective
Anish Madan, Mansi Garg, Garvit Satija, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 14, pp. 1319-1339
Closed Access | Times Cited: 6
Comparative Analysis of the Interaction between the Antiviral Drug Umifenovir and Umifenovir Encapsulated in Phospholipids Micelles (Nanosome/Umifenovir) with dsDNA as a Model for Pharmacogenomic Analysis by Electrochemical Methods
Victoria V. Shumyantseva, Tatiana V. Bulko, Lyubov E. Agafonova, et al.
Processes (2023) Vol. 11, Iss. 3, pp. 922-922
Open Access | Times Cited: 6
Selective Buchwald–Hartwig arylation ofC-amino-1,2,4-triazoles and other coordinating aminoheterocycles enabled by bulky NHC ligands and TPEDO activator
Alexander V. Astakhov, Andrey Yu. Chernenko, Vadim V. Kutyrev, et al.
Inorganic Chemistry Frontiers (2022) Vol. 10, Iss. 1, pp. 218-239
Closed Access | Times Cited: 8
Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine
Tamás Kálai, Judit E. Pongrácz, Péter Mátyus
Chemistry (2022) Vol. 4, Iss. 2, pp. 216-258
Open Access | Times Cited: 7
Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors
Suyash Pant, N. R. Jena
European Journal of Pharmaceutical Sciences (2021) Vol. 167, pp. 106012-106012
Open Access | Times Cited: 8
Recent Insights of SARS-CoV-2 Potential Inhibitors
Mohd. Faheem, Vinay Kumar Singh, Abhishek Srivastava
Biomedical and Biotechnology Research Journal (BBRJ) (2022) Vol. 6, Iss. 1, pp. 21-32
Open Access | Times Cited: 5
COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies
Vishal Singh, Himani Chaurasia, Richa Mishra, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 27, pp. 2211-2233
Closed Access | Times Cited: 4
Hydroxyl radical-induced C1′-H abstraction reaction of different artificial nucleotides
N. R. Jena, P. K. Shukla
Journal of Molecular Modeling (2024) Vol. 30, Iss. 10
Closed Access
COVID-19 treatment: Nattokinase, a fibrinolytic serine protease is the low-hanging fruit
Basil N. Okeahialam
Santosh University Journal of Health Sciences (2024) Vol. 10, Iss. 2, pp. 279-282
Closed Access
In silico and in vitro assays reveal potential inhibitors against 3CLpro main protease of SARS-CoV-2
Eldhose Iype, Jisha Pillai U, Indresh Kumar, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 23, pp. 12800-12811
Open Access | Times Cited: 4
Current trends in diagnosis and treatment strategies of COVID-19 infection
Varsha Tiwari, Manish Kumar, Abhishek Tiwari, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 46, pp. 64987-65013
Open Access | Times Cited: 4
Proposing lead compounds for the development of SARS-CoV-2 receptor-binding inhibitors
Elvis Awuni, Radiatu Abdallah Musah
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 5, pp. 2282-2297
Closed Access | Times Cited: 1
Peptide inhibitors derived from the nsp7 and nsp8 cofactors of nsp12 targeting different substrate binding sites of nsp12 of the SARS-CoV-2
N. R. Jena, Suyash Pant
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 13, pp. 7077-7089
Closed Access | Times Cited: 1
Cannabis Addiction and COVID-19 Protocols: Are Safety and Efficacy Issues Questionable?
Mohamed A. Raslan, M. S. Eslam, A. R. Sara, et al.
Saudi Journal of Medical and Pharmaceutical Sciences (2022) Vol. 8, Iss. 6, pp. 297-305
Open Access | Times Cited: 1
An In-silico Multi-Targeted Approach in Search of Potential Drug Candidate( s) Against SARS-CoV-2 Lung Infection
Joohee Pradhan, Kapish Kapoor, Vishnu Das, et al.
Coronaviruses (2022) Vol. 3, Iss. 6
Closed Access | Times Cited: 1
De Novo Drug Design of Potential Inhibitors of the Receptor-Binding Domain of SARS-CoV-2 Variants
Edgar Clyde R. Lopez
(2023), pp. 38-38
Open Access
Antiviral peptides inhibiting the main protease of SARS‐CoV‐2 investigated by computational screening and in vitro protease assay
James T. Stewart, Jakaria Shawon, Muhammad Ali, et al.
Journal of Peptide Science (2023) Vol. 30, Iss. 4
Open Access
RNA-dependent RNA Ploymerase of SARS-CoV-2 as an Attractive Drug Target to Contain COVID-19
N. R. Jena
(2022)
Closed Access
Covid – 19 infection and treatment: Still an unfolding clinical scenario
Basil N. Okeahialam
Santosh University Journal of Health Sciences (2022) Vol. 8, Iss. 2, pp. 169-171
Closed Access
Page 1

Scroll to top